Keywords: ایکسژیزمب; 4 years; interleukin 17; ixekizumab; long-term; open-label; psoriasis; BCC; basal cell carcinoma; DLQI; Dermatology Life Quality Index; HADS; Hospital Anxiety and Depression Scale; IBD; inflammatory bowel disease; IL; interleukin; LOCF; last observation c
مقالات ISI ایکسژیزمب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ایکسژیزمب; Psoriasis; psoriatic arthritis; autoantigens; IL-17; IL-23; secukinumab; ixekizumab; brodalumab; tildrakizumab, guselkumab, and risankizumab; ADAMTSL5; A disintegrin-like and metalloprotease domain containing thrombospondin type 1 motif-like 5; AMP; Antim
Keywords: ایکسژیزمب; Anti-IL-17 agents; Interleukin-17; Ixekizumab; Psoriasis; Agentes anti IL-17; Interleucina-17; Ixekizumab; Psoriasis;
Keywords: ایکسژیزمب; biologic therapy; Crohn's disease; inflammatory bowel disease; interleukin-17 antagonists; ixekizumab; psoriasis; ulcerative colitis; AE; adverse event; CD; Crohn's disease; EPIMAD; Registre Epidemiologique des Maladies de l'Appareil Digestif; IBD; inflam
Keywords: ایکسژیزمب; Psoriasis; Psoriatic arthritis; Infection; Secukinumab; Ixekizumab; Brodalumab;
Evaluation of circulating invariant T cells before and after IL-17 inhibitor treatment in a patient with psoriatic arthritis
Keywords: ایکسژیزمب; Psoriatic arthritis; Ixekizumab; γδT cells; iNKT cells; Th17 cells;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobuli
Keywords: ایکسژیزمب; Anakinra; Brodalumab; Canakinumab; Eculizumab; Infection; Ixekizumab; Prevention; Rilonacept; Secukinumab; Tocilizumab;
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108Â weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Keywords: ایکسژیزمب; efficacy; interleukin 17; ixekizumab; long-term; psoriasis; safety; UNCOVER-3; AE; adverse event; CI; confidence interval; IL; interleukin; LTE; long-term extension; MI; multiple imputation; mMI; modified multiple imputation; NAPSI; Nail Psoriasis Severit
Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys
Keywords: ایکسژیزمب; Cynomolgus monkey; Embryo-fetal; Fertility; Ixekizumab; Pre-postnatal; Toxicity;
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
Keywords: ایکسژیزمب; interleukin 17; ixekizumab; long-term; monoclonal antibodies; open label; psoriasis; 1 year; AE; adverse event; NRI; nonresponder imputation; OLE; open-label extension; PASI; Psoriasis Area and Severity Index; PASI75; 75% improvement from baseline on the
Th17 cells and IL-17 A-Focus on immunopathogenesis and immunotherapeutics
Keywords: ایکسژیزمب; Th17 cells; Interleukin-17; Secukinumab; Ixekizumab; Brodalumab;